FDA Grants Breakthrough Therapy Designation to Latozinemab for FTD-GRN
核心洞察
The FDA has granted Breakthrough Therapy Designation to latozinemab for frontotemporal dementia (搜索) with a progranulin gene mutation (FTD-GRN (搜索)).
Latozinemab, developed by Alector and GSK, is a monoclonal antibody that elevates progranulin levels by blocking sortilin (搜索).
The designation was based on Phase 2 clinical trial data, indicating substantial improvement over available therapies for this rare, rapidly progressing disease.
The FDA has granted Breakthrough Therapy Designation to latozinemab, an investigational human monoclonal antibody, for the treatment of frontotemporal dementia (搜索) with a progranulin gene mutation (FTD-GRN (搜索)). This designation aims to expedite the development and review of drugs that show promise in treating serious conditions where preliminary clinical evidence indicates substantial improvement over existing therapies.
Mechanism of Action and Clinical Development
Latozinemab, also known as AL001, is designed to elevate progranulin (PGRN) levels by inhibiting sortilin (搜索), a degradation receptor for PGRN. PGRN is a key regulator of immune activity in the brain, with genetic links to neurodegenerative disorders, including FTD, Alzheimer’s disease (搜索), and Parkinson’s disease (搜索). The drug is currently in the pivotal INFRONT-3 Phase 3 study, which completed target enrollment in October 2023.
Rationale for Breakthrough Therapy Designation
The FDA's decision was based on data from the INVOKE-2 Phase 2 clinical trial, which demonstrated latozinemab's potential to significantly improve outcomes for FTD-GRN (搜索) patients. Breakthrough Therapy Designation is reserved for drugs that may offer a substantial improvement over available therapies for serious conditions.
Frontotemporal Dementia and Unmet Needs
FTD is a rare neurodegenerative disease and a common cause of early-onset dementia, affecting an estimated 50,000 to 60,000 people in the United States and roughly 110,000 in the European Union. FTD-GRN (搜索), a heritable form of FTD, accounts for 5% to 10% of all FTD cases. Patients typically develop symptoms such as behavioral changes, impaired judgment, and language difficulties in their 40s and 50s, with the disease progressing over 7-10 years. Currently, there are no FDA-approved treatments for any form of FTD.
Collaboration between Alector and GSK
Alector and GSK are collaborating on the global development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab. Under the terms of their agreement, Alector received $700 million in upfront payments and is eligible for up to $1.5 billion in additional milestone payments. In the United States, the companies will equally share profits and losses, while Alector will receive tiered royalties for sales outside the United States.
Quote from Alector's CEO
"In partnership with GSK, we are encouraged and excited by this FDA Breakthrough Designation," said Arnon Rosenthal, Ph.D., Chief Executive Officer of Alector. "With this designation, we look forward to continued productive conversations with the FDA, recognizing the unmet need for people living with FTD-GRN (搜索), a serious condition for which there are no FDA-approved treatment options available."